- Case Report
- Open Access
A case of adrenocortical carcinoma accompanying secondary acute adrenal hypofunction postoperation
© The Author(s). 2018
Received: 18 August 2017
Accepted: 30 January 2018
Published: 5 March 2018
Adrenocortical carcinoma (ACC) is a rare, heterogeneous malignancy with a poor prognosis. ACCs are classified as functioning and non-functioning. The pathogenesis of ACC remains elusive, and diagnosis of ACC is currently based on pathology. In the absence of other effective approaches, surgical resection is the preferred treatment option.
Here, we report a case of ACC in the retroperitoneum. The patient underwent radical adrenalectomy and remained disease-free throughout a 6-month follow-up.
Radical surgical resection is an efficient therapy for ACC, and hydrocortisone can be used to alleviate symptoms of secondary acute adrenal hypofunction.
Adrenocortical carcinoma (ACC) is a rare, heterogeneous malignancy with a very poor prognosis. The overall incidence of ACC is approximately 0.5–2 cases per million per year , and it accounts for approximately 0.02–0.2% of all cancer-related deaths . ACCs are classified as functional or nonfunctional based on the hormonal syndromes they produce. Functioning ACC usually manifests with hormonal syndromes, including virilization, Cushing’s syndrome, Con’s syndrome, and feminization. Nonfunctioning adrenal tumors remain a challenge in terms of early diagnosis and successful management, as there are no early signs or symptoms of disease .
Currently, the diagnosis of ACC is based on pathology and dependent on the Weiss score, tumor size, and underlying genetic predisposition . Weissferdt et al. demonstrated positive staining for steroid receptor coactivator-1 (SRC-1) (39/40; 97.5%), inhibin-α (37/40; 92.5%), calretinin (32/40; 80%), synaptophysin (29/40; 72.5%), melan A (26/40; 65%), and cell adhesion molecule (CAM) 5.2 (9/40; 22.5%) in ACC . Several genes and pathways with potential for use as diagnostic or prognostic markers have been identified using comparative genomic hybridization, DNA methylation profiling, and genome-wide mRNA and miRNA expression profiling .
Surgery is the mainstay treatment option for ACC. Chalasani et al.  reported that stage I and stage II ACC can be cured by surgical treatment, while an appropriate dose of oral mitotane may be beneficial for stage III and stage IV diseases.
Here, we report a case of a 31-year-old woman who was diagnosed with ACC. The patient was treated with left radical adrenalectomy and then followed up with physical assessments, laboratory testing, and imaging, including X-rays and computed tomography (CT) scans. At the 6-month follow-up, she remained disease-free.
A 31-year-old woman presented with abdominal pain and fever for 4 days and unintended, excessive weight loss of 15 kg over the previous 2 months. Physical examination revealed vital signs within the normal range, except for intermittent fever reaching a maximum temperature of 39 °C once or twice a day. The patient had been ordinarily healthy, although she had a 15-year history of smoking. The patient had undergone two cesarean sections in January 2006 and June 2015 and had a 12-cm postoperative scar on the lower abdomen. In addition, she had a large palpable mass in the left abdomen.
Laboratory testing revealed a hemoglobin level of 112 g/L (normal, 115–150 g/L), indicating mild anemia. Coagulation parameters were: prothrombin time 14.8 s (normal, 9–13 s), international normalized ratio 1.26 (normal, 0.8–1.2 s), prothrombin activity 69 (normal, 80–120), and fibrinogen 7.65 g/L (normal, 2–4 g/L), suggesting coagulation was impaired. The tumor marker neuron-specific enolase was abnormally elevated at 35.84 ng/ml (normal, < 25 ng/ml). Liver function tests, urinalysis, serum electrolyte levels, and fasting blood glucose concentrations were normal.
We report the case of a 31-year-old female who underwent radical surgical resection of a mixed solid and cystic lesion in the left upper quadrant of the abdomen. Postoperatively, the patient experienced intermittent fever and rash. Her symptoms resolved after hydrocortisone treatment, indicating that they were due to secondary acute adrenal hypofunction.
According to the 2004 World Health Organization (WHO) classification, ACC variants include oncocytic ACCs, myxoid ACCs, and ACCs with sarcomatous areas. Patients of all ages can present with ACC, but it has a bimodal age distribution with peaks in the first and fourth decades. Evidence suggests that approximately 60% of tumors are functional , and that patients may present with Cushing’s syndrome, virilization, feminization, or hypertension resulting from excessive secretion of glucocorticoids, androgens, estrogens, or aldosterone, respectively. Due to their silent nature, nonfunctioning tumors remain undiagnosed until late stage disease, when they mostly present as a large mass, as in the current case. Adrenocortical tumors are associated with weight loss, weakness, fever, and myalgias , as experienced by our patient, who also suffered from intermittent rash after surgery due to secondary acute adrenal hypofunction.
The pathogenesis of ACC remains elusive, but some molecular mechanisms have been implicated in its development, including pathways involving tumor protein 53 (TP53), insulin-like growth factor-2 (IGF-2), and β-catenin. In some studies, the presence of inactivating TP53 mutations and activating β-catenin mutations in ACC on transcriptome analysis was associated with worse prognosis. Several genome-wide expression studies demonstrated that IGF-2 can be used in combination with Ki-67, with 96% sensitivity and 100% specificity, in the diagnosis of ACC .
According to the TNM (tumor [T], lymph node [N], distant metastasis [M]) system of the American Joint Committee on Cancer, clinical staging of ACC includes: stage I, stage II, stage III, and stage IV . In general, the larger the tumor, the greater the potential for malignancy . Common metastatic sites include lung and liver, and less common sites are bone and bone marrow . CT scanning plays an important role in defining the extent of the primary tumor as well as assessing the presence of metastatic disease.
Several clinical features are helpful in the diagnosis of ACC, including a high Weiss score, large tumor size, and underlying genetic predisposition, but definitive diagnosis depends on pathology. Metastasizing adrenocortical tumors are categorized by five histologic features, including capsular invasion, vascular invasion, diffuse tumor growth, spindle-cell morphology, and nuclear heterogeneity; malignant tumors have at least three of these features . In the current case, a diagnosis of stage III ACC was reached based on the tumor size and enlargement of lymph nodes.
Surgical resection is the mainstay treatment for ACC . Radical surgery represents nephrectomy, adrenalectomy, and resection of the surrounding lymph nodes. In some cases, multiple visceral resections are required to achieve a complete R0 resection.
Bacalbasa et al.  reported the case of a 65-year-old patient treated with a complete resection en bloc with left nephrectomy and adrenalectomy, distal pancreatectomy, splenectomy, left colectomy, and para-aortic lymph node dissection. In the modern pursuit of minimally invasive technology with respect to aesthetics, posterior retroperitonoscopic adrenalectomy (PRA) has become a standard approach for removal of the adrenal gland .
In recent years, mitotane has been advocated as a therapy following the resection of a localized tumor  and for metastatic disease. Sabolch et al.  showed that radiotherapy significantly lowered the risk of local recurrence/progression in patients with ACC. Increasing our understanding of the pathogenesis of ACC may provide potential treatment targets, including 9-cisRA , miRNAs , and topoisomerase 2-alpha (TOP2A) .
ACC has a poor prognosis with frequent recurrence and metastases even after complete resection. The median survival times for patients with stage I–II, stage III, and stage IV diseases are 159 months (95% confidence interval [CI], 93–225 months), 26 months (95% CI, 4–48 months), and 5 months (95% CI, 2–7 months), respectively . Our patient was still disease-free at 6 months after tumor resection.
Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.
LGY contributed to the conception of the study. ZHW, ZCG, and XEB contributed significantly to case analysis and manuscript preparation. KK performed the data analyses and wrote the manuscript. CYG and WGY helped perform the analysis with constructive discussions. All authors approved the final version for publication.
Ethics approval and consent to participate
The study protocol was approved by the ethical committee of Bethune Hospital 1, China. Written consent for publication of the case was obtained.
All authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Yokoyama H, Adachi T, Tsubouchi K, Tanaka M, Sasano H. Non-functioning adrenocortical carcinoma arising in an adrenal rest: immunohistochemical study of an adult patient. Tohoku J Exp Med. 2013;229(4):267–70.View ArticlePubMedGoogle Scholar
- Ye J, Qi Y, Wang W, Sun F, Wei Q, Su T, et al. Lower expression of ATM and gene deletion is more frequent in adrenocortical carcinomas than adrenocortical adenomas. Endocrine. 2012;41(3):479–86. https://doi.org/10.1007/s12020-012-9593-3.View ArticlePubMedGoogle Scholar
- Patel VV, Shah DS, Raychaudhari CR, Patel KB. Giant non-functioning adrenocortical carcinoma: a rare childhood tumor. Indian J Med Paediatr Oncol. 2010;31(2):65–8. https://doi.org/10.4103/0971-5851.71659.View ArticlePubMedPubMed CentralGoogle Scholar
- Sakoda A, Mushtaq I, Levitt G, Sebire NJ. Clinical and histopathological features of adrenocortical neoplasms in children: retrospective review from a single specialist center. J Pediatr Surg. 2014;49(3):410–5. https://doi.org/10.1016/j.jpedsurg.2013.09.008.View ArticlePubMedGoogle Scholar
- Weissferdt A, Phan A, Suster S, Moran CA. Adrenocortical carcinoma: a comprehensive immunohistochemical study of 40 cases. Appl Immunohistochem Mol Morphol. 2014;22(1):24–30. https://doi.org/10.1097/PAI.0b013e31828a96cf.View ArticlePubMedGoogle Scholar
- Lerario AM, Moraitis A, Hammer GD. Genetics and epigenetics of adrenocortical tumors. Mol Cell Endocrinol. 2014;386(1–2):67–84. https://doi.org/10.1016/j.mce.2013.10.028.View ArticlePubMedGoogle Scholar
- Chalasani S, Vats HS, Banerjee TK, McKenzie AK. Metastatic virilizing adrenocortical carcinoma: a rare case of cure with surgery and mitotane therapy. Clin Med Res. 2009;7(1–2):48–51. https://doi.org/10.3121/cmr.2009.821.View ArticlePubMedPubMed CentralGoogle Scholar
- Allolio B, Fassnacht M. Clinical review: Adrenocortical carcinoma: clinical update. J Clin Endocrinol Metab. 2006;91(6):2027–37. https://doi.org/10.1210/jc.2005-2639.View ArticlePubMedGoogle Scholar
- Agrons GA, Lonergan GJ, Dickey GE, Perez-Monte JE. Adrenocortical neoplasms in children: radiologic-pathologic correlation. Radiographics. 1999;19(4):989–1008. https://doi.org/10.1148/radiographics.19.4.g99jl14989.View ArticlePubMedGoogle Scholar
- Dackiw AP, Lee JE, Gagel RF, Evans DB. Adrenal cortical carcinoma. World J Surg. 2001;25(7):914–26.View ArticlePubMedGoogle Scholar
- Bacalbasa, Nicolae, Terzea, et al. Multiple visceral resection for Giant non-Secretory Adrenocortical carcinoma in an elderly patient: a case report [J]. Anticancer Res: Int J Cancer Res Treat. 2015;(4):2169–74.Google Scholar
- Bakkar S, Materazzi G, Fregoli L, et al. Posterior retroperitonoscopic adrenalectomy: a back door access with an unusually rapid learning curve [J]. Update Surg Italy. 2017;69(2):235–9.View ArticleGoogle Scholar
- Kasperlik-Zaluska AA. Clinical results of the use of mitotane for adrenocortical carcinoma. Braz J Med Biol Res. 2000;33(10):1191–6.View ArticlePubMedGoogle Scholar
- Sabolch A, Feng M, Griffith K, Hammer G, Doherty G, Ben-Josef E. Adjuvant and definitive radiotherapy for adrenocortical carcinoma. Int J Radiat Oncol Biol Phys. 2011;80(5):1477–84. https://doi.org/10.1016/j.ijrobp.2010.04.030.View ArticlePubMedGoogle Scholar
- Szabo DR, Baghy K, Szabo PM, Zsippai A, Marczell I, Nagy Z, et al. Antitumoral effects of 9-cis retinoic acid in adrenocortical cancer. Cell Mol Life Sci. 2014;71(5):917–32. https://doi.org/10.1007/s00018-013-1408-z.View ArticlePubMedGoogle Scholar
- Jain M, Zhang L, He M, Zhang YQ, Shen M, Kebebew E. TOP2A is overexpressed and is a therapeutic target for adrenocortical carcinoma. Endocr Relat Cancer. 2013;20(3):361–70. https://doi.org/10.1530/ERC-12-0403.View ArticlePubMedPubMed CentralGoogle Scholar
- de Krijger RR, Papathomas TG. Adrenocortical neoplasia: evolving concepts in tumorigenesis with an emphasis on adrenal cortical carcinoma variants. Virchows Arch. 2012;460(1):9–18. https://doi.org/10.1007/s00428-011-1166-y.View ArticlePubMedGoogle Scholar